Genentech: Raptiva patient has PML

A potentially deadly brain infection has reared its head in another drug population. This time, Genentech is warning doctors that a patient treated with its psoriasis drug Raptiva has developed progressive multifocal leukoencephalopathy, or PML. It's the second time in a month that Genentech has seen PML crop up among its patients; in September, a rheumatoid arthritis patient taking Rituxan died from the same infection.

And as you know, it's the same brain malady that has plagued Biogen Idec and Elan: It forced the multiple sclerosis drug Tysabri off the market until Biogen and FDA agreed on a strict risk-management program. Since then, two new cases have emerged, but though the FDA is adding that info to Tysabri's label, it deemed any further regulatory action unnecessary.

The latest PML case was reported to Genentech late last month as part of its safety monitoring program. "[B]ased on the medical information available to date, Raptiva may have had a contributory role in the development of PML in this patient," Genentech said. The company's overseas partner, Merck Serono, said it has let other regulatory agencies know about the case and is working with European watchdogs to update Raptiva's product info.

- see Genentech's release
- read the story at PharmaTimes

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Implementing data integration strategy in your commercialization breaks down traditional healthcare silos and improves patient outcomes.

Roche and Blueprint's RET inhibitor Gavreto has won FDA go-ahead to treat certain types of thyroid cancer, leveling the field with Lilly's Retevmo.

CDMO Sterling Pharma Solutions is plotting a buyout of a U.K.-based antibody-drug conjugate specialist in a new bid at the next-gen cancer fighters.